This HTML5 document contains 76 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n26http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00754/identifier/chemspider/
n16http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00754/identifier/chebi/
n17http://linked.opendata.cz/resource/drugbank/dosage/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00754/identifier/wikipedia/
n23http://bio2rdf.org/drugbank:
n24http://linked.opendata.cz/resource/drugbank/drug/DB00754/identifier/pharmgkb/
n5http://linked.opendata.cz/resource/drugbank/drug/DB00754/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00754/identifier/pubchem-compound/
n30http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00754/identifier/pubchem-substance/
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00754/identifier/kegg-drug/
n18http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n9http://linked.opendata.cz/ontology/drugbank/
n14http://www.drugs.com/cdi/
n15http://linked.opendata.cz/resource/drugbank/property/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00754/identifier/drugbank/
n21http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00754/identifier/national-drug-code-directory/
n29http://linked.opendata.cz/resource/atc/
n28http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00754
rdf:type
n9:Drug
n9:description
Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin is no longer commonly used.
n9:dosage
n17:271B5851-363D-11E5-9242-09173F13E4C5
n9:generalReferences
# SCHWADE ED, RICHARDS RK, EVERETT GM: Peganone, a new antiepileptic drug. Dis Nerv Syst. 1956 May;17(5):155-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/13317788
n9:group
approved
n9:halfLife
3 to 9 hours
n9:indication
For the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures.
n9:manufacturer
n16:271B584F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n23:DB00754 n30:DB00754
dcterms:title
Ethotoin
adms:identifier
n5:C07839 n6:D00708 n7:3176 n8:DB00754 n10:3292 n11:46504521 n12:67386-601-01 n24:PA164768735 n25:Ethotoin n27:4888
n9:mechanismOfAction
The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin inhibits nerve impulses in the motor cortex by lowering sodium ion influx, limiting tetanic stimulation.
n9:packager
n16:271B584D-363D-11E5-9242-09173F13E4C5 n16:271B584E-363D-11E5-9242-09173F13E4C5 n16:271B584C-363D-11E5-9242-09173F13E4C5
n9:synonym
3-Ethyl-5-phenylhydantoin 3-Ethyl-5-phenylimidazolidin-2,4-dione 3-Ethyl-5-phenyl-2,4-imidazolidinedione 3-Ethyl-5-phenyl-imidazolidine-2,4-dione Ethotoinum Ethotoin 1-Ethyl-2,5-dioxo-4-phenylimidazolidine (+-)-3-Ethyl-5-phenylhydantoin Etotoina Ethotoïne
n9:toxicity
Symptoms of overdose include drowsiness, loss of or impaired muscle coordination, nausea, visual disturbance, and, at very high doses, coma.
n9:synthesisReference
Close, W.J.; U.S. Patent 2,793,157; May 21, 1957; assigned to Abbott Laboratories.
n18:hasConcept
n19:M0224736
foaf:page
n14:ethotoin.html n21:peg1665.shtml n26:peganone.htm
n9:IUPAC-Name
n15:271B5856-363D-11E5-9242-09173F13E4C5
n9:InChI
n15:271B585C-363D-11E5-9242-09173F13E4C5
n9:Molecular-Formula
n15:271B585B-363D-11E5-9242-09173F13E4C5
n9:Molecular-Weight
n15:271B5858-363D-11E5-9242-09173F13E4C5
n9:Monoisotopic-Weight
n15:271B5859-363D-11E5-9242-09173F13E4C5
n9:SMILES
n15:271B585A-363D-11E5-9242-09173F13E4C5
n9:Water-Solubility
n15:271B586C-363D-11E5-9242-09173F13E4C5 n15:271B5854-363D-11E5-9242-09173F13E4C5
n9:logP
n15:271B586E-363D-11E5-9242-09173F13E4C5 n15:271B5855-363D-11E5-9242-09173F13E4C5 n15:271B5852-363D-11E5-9242-09173F13E4C5
n9:logS
n15:271B5853-363D-11E5-9242-09173F13E4C5
n28:hasATCCode
n29:N03AB01
n9:H-Bond-Acceptor-Count
n15:271B5862-363D-11E5-9242-09173F13E4C5
n9:H-Bond-Donor-Count
n15:271B5863-363D-11E5-9242-09173F13E4C5
n9:InChIKey
n15:271B585D-363D-11E5-9242-09173F13E4C5
n9:Polar-Surface-Area--PSA-
n15:271B585E-363D-11E5-9242-09173F13E4C5
n9:Polarizability
n15:271B5860-363D-11E5-9242-09173F13E4C5
n9:Refractivity
n15:271B585F-363D-11E5-9242-09173F13E4C5
n9:Rotatable-Bond-Count
n15:271B5861-363D-11E5-9242-09173F13E4C5
n9:absorption
Fairly rapidly absorbed, however, the extent of oral absorption is not known.
n9:affectedOrganism
Humans and other mammals
n9:casRegistryNumber
86-35-1
n9:category
n9:containedIn
n20:271B5850-363D-11E5-9242-09173F13E4C5
n9:Bioavailability
n15:271B5868-363D-11E5-9242-09173F13E4C5
n9:Ghose-Filter
n15:271B586A-363D-11E5-9242-09173F13E4C5
n9:MDDR-Like-Rule
n15:271B586B-363D-11E5-9242-09173F13E4C5
n9:Melting-Point
n15:271B586D-363D-11E5-9242-09173F13E4C5
n9:Number-of-Rings
n15:271B5867-363D-11E5-9242-09173F13E4C5
n9:Physiological-Charge
n15:271B5866-363D-11E5-9242-09173F13E4C5
n9:Rule-of-Five
n15:271B5869-363D-11E5-9242-09173F13E4C5
n9:Traditional-IUPAC-Name
n15:271B5857-363D-11E5-9242-09173F13E4C5
n9:pKa--strongest-acidic-
n15:271B5864-363D-11E5-9242-09173F13E4C5
n9:pKa--strongest-basic-
n15:271B5865-363D-11E5-9242-09173F13E4C5